Company: CRVO
Filing Date: 2025-12-05
Form Type: 8-K
Source: 0001437749-25-037025
Chunk: 0

Company: CervoMed Inc.
Filing Date: 2025-12-05
Form: 8-K
Item: Item 7.01
Chunk 0
---

Item 7.01   Regulation FD Disclosure
------------------------------------
Press Releases
 
On December 2, 2025, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release (the “December 2 Press Release”) announcing new plasma biomarker data from our Phase 2b RewinD-LB trial (the “RewinD-LB Trial”) demonstrating neflamapimod treatment led to improvements in neuroinflammation and neurodegeneration in patients with dementia with Lewy bodies (“DLB”) presented at the 18th Clinical Trials on Alzheimer's Disease (“CTAD”) Conference in San Diego, California on December 1, 2025. A copy of the December 2 Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
 
On December 4, 2025, we issued a press release (the “December 4 Press Release”) announcing that clinical investigators shared the full results of the RewinD-LB Trial in a late-breaking oral session at the CTAD Conference on December 4, 2025. A copy of the December 4 Press Release is attached hereto as Exhibit 99.2 and incorporated herein by reference.
 
Presentations
 
Certain information concerning the business, clinical studies, development plans, financial position and related matters of the Company, including the data and other information from the RewinD-LB Trial presented at the CTAD Conference, has been made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.
 
The information contained in the presentation is summary information that is intended to be considered in the context of the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”) and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the